Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesClinically significant carbapenemases: an update
Current Opinion in Infectious Diseases, 07/03/08
Walsh TR - Carbapenem resistance continues to increase both in number and into new species/strain types, but the therapeutic options remain woefully inadequate - a dilemma that will not improve in the foreseeable future.
Related Articles
Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre
Journal of Medical Microbiology, 10/22/09
Relevance Score: 84%
Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae
Infection Control and Hospital Epidemiology, 10/28/09
Relevance Score: 80%
Novel Genetic Environment of the Carbapenem-Hydrolyzing beta-Lactamase KPC-2 among Enterobacteriaceae in China
Antimicrobial Agents and Chemotherapy, 10/06/09
Relevance Score: 80%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study
Diagnostic Microbiology and Infectious Disease, 12/09/09
Screening of some Tanzanian medicinal plants for their trypanocidal and cytotoxic activities
Phytotherapy Research, 12/09/09
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
The Lancet - Early Online Publication, 12/09/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Sponsor
Article Search
Sponsor